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 Abstract  
Objective: To test the diagnostic accuracy of SWE for the detection and phenotypic characterisation 
of PCa compared with whole-mount radical prostatectomy histopathology.    
Materials and Methods:   This was a prospective protocol-driven diagnostic accuracy study. 212 
consecutive men undergoing laparoscopic radical prostatectomy (LRP) for clinically localised PCa 
were recruited into the study. Quantitative stiffness data of the prostate gland was obtained in each 
patient using an endocavitary transrectal transducer before LRP and compared with detailed 
histopathological examination of radical prostatectomy specimen using 3-D printing mold based 
technology ensuring improved image-histology orientation. Receiver operator characteristic curves 
(ROC) were assessed between the groups. 
Results and limitations:  Quantitative stiffness data estimated in kilopascals (kPa) was significantly 
higher in malignant compared with benign areas.  With a cut-off value of 82.6 kPa, sensitivity and 
specificity of SWE were 96.8% and 67.8%, respectively (p<0.05). Significant differences were 
observed for different grades of cancer with Young’s moduli 91.6kPa, 102.3kPa and 131.8kPa for low 
(Gleason score 6), intermediate (Gleason score 7) and high grade (Gleason score ≥ 8) PCa 
respectively (p<0.05). SWE also detected capsular breaches with significant prediction of PCa 
pathologic staging. Potential limitations include selection bias and study being single centre site. 
Conclusions:  Quantitative SWE via transrectal approach accurately detected cancer foci and showed 
significant differences between cancerous and benign tissue. Moreover, this technique can be used 
to reliably phenotype PCa aggressiveness.   
Introduction 
Prostate cancer (PCa) accounts for the second most frequently diagnosed male cancer worldwide [1, 
2]. Screening studies focusing on PCa detection by prostate-specific antigen (PSA) and digital rectal 
examination (DRE) as primary methods demonstrate that these approaches result in unnecessary 
biopsies, misdiagnosis and  over-treatment of patients, in particularly those with  insignificant PCa [3, 
4].  
Patients diagnosed with localised PCa are offered either active surveillance or radical treatments.  
Radical treatments are invariably accompanied by high adjunct health risks and are financially costly.  
Particularly, patients are paying a high price for low-risk diseases.  Accurate detection of clinically 
significant PCa using non-invasive imaging may allow for improved risk stratification and optimal 
selection of men for active surveillance, focal therapy, and/or radical therapy. 
Transrectal ultrasound (TRUS) is a non-invasive imaging method.  Compared with other imaging 
techniques such as MRI and CT, TRUS is more practical in the clinical setting with advantages of real-
time, cost-effective and radiation-free [5].  Nevertheless, traditional B-mode and Doppler ultrasound 
images demonstrate limited sensitivity and/or specificity and have not proven to unequivocally 
improve diagnostic accuracy of PCa detection[6].   
Malignant tissue associated with the prostate gland is stiffer compared to the surrounding benign 
enlargement. This is well-recognised by clinicians performing DRE. Information derived from DRE is 
important for the clinical decision-making process. However, independently performed DRE 
demonstrates  poor sensitivity and specificity for assessing small and anteriorly located lesions[7].  
Accordingly, with the recent introduction of TRUS shear wave elastography (SWE), it is possible to 
assess tissue stiffness even for non-palpable small lesions. The SWE technique is based on 
measurements of shear wave speed through target tissues, which can be used to dynamically map 
and reflect tissue stiffness (Young’s modulus) properties in real time[8, 9].  Preliminary studies using 
SWE have been promising and suggest by implementing this technique[10], there is  potential for 
improved  cancer detection and phenotyping [11]. The technology is briefly described: shear wave 
pulse is generated within the target tissue by multiple focused ultrasound beams, the difference in 
speed of shear waves is due to the stiffness properties of propagating medium; this difference is 
captured by piezo-electrodes inside the transducer including all these scattered shear waves and 
they are plotted in a pseudo-colour-coded map with shear wave speed (m/s) or Young’s modulus 
(kPa) in pixel overlapped with B-mode ultrasound (Figure 1).  
We and others have previously reported SWE for detecting and phenotyping PCa, and demonstrated 
strong diagnostic performance of this methodology  [11-15].  Nevertheless, to date there have been 
no large-scale prospective studies that have tested the diagnostic accuracy of SWE compared with 
radical prostatectomy histology as reference standard.    
Accordingly, this prospective study aimed to:  
1.  Determine the diagnostic accuracy of transrectal SWE compared with the final pathology of 
radical prostatectomy.  
2. Determine the reliability of transrectal SWE with respect to accurately characterise phenotyping 
various grades of PCa including establishing and validating cut-offs for benign and significant PCa. 
Methods 
 
Study population 
This was a prospective protocol-driven study demonstrating prior ethical and institutional approvals 
(Research Ethical Committee (REC) number 13/ES/0099, Research & Development number 
2012ON32) designed to assess the diagnostic accuracy of transrectal SWE ultrasound specifically for 
PCa.  Between November 2013 and August 2017, 218 consecutive participants with clinically 
localized PCa opting and scheduled to LRP were recruited into the study, 6 patients were excluded 
because of (1) prostate specimens were sectioned and analysed by non-study pathologists (n=4) and 
(2) SWE data were not adequate for analysis (n=2). The basic demographic characteristics is 
presented in Table 1.  Using  previously defined criterion thresholds [16],  participants were divided 
into low, intermediate or  high risk PCa groups.  
The primary outcome of the study was to determine the diagnostic accuracy of transrectal SWE for 
the detection and phenotyping of PCa.   The secondary outcome was to determine the ability of the 
technology in detecting clinically significant PCa and to define risk threshold cut-off values for SWE. 
The presence of clinically significant PCa was defined based on a combination of Gleason grade (>6) 
and physical cancer burden (>5mm)[17]. 
Study inclusion criteria were men with confirmed PCa on TRUS guided biopsies coupled with imaging 
suggestive of clinically localised disease (clinically ≤T2c).  Based on sample size calculated, 170 
patients were required to address primary outcome. All significance calculations were two sided and 
based on α set at 0.05, power equal to 0.95 and effect size of 0.3.  We recruited 212 men into the 
study to account for an estimated 20% loss of data (participant drop out, poor images, technical 
difficulties, etc.).    
 
Transrectal Ultrasound SWE imaging Protocol-Index test 
TRUS SWE was performed by an experienced urologist (more than 10 years of experience) on the 
same day of LRP for all participants using an endocavity Aixplorer® ultrasound transducer 
(SuperSonic Imagine, Aix-en-Provence, France) through the rectal wall focussing on the prostate 
avoiding any pressure on the transducer.  During patient imaging, prostate glands were scanned in 
axial and sagittal planes from base to apex every 4~6 mm.  Quantitative analyses of images were 
performed following examinations, imaging data of successive planes was used to construct off-line 
3D images of the prostate. Participant images were then used to produce customised prostate molds, 
which were then used to guide slicing of the prostate following surgery.  
 
Histopathology of radical prostatectomy as reference test  
All eligible participants’ prostate specimens were sectioned according to our recently published 
method [18].  Briefly, we applied rapid prototyping methodology using prostate images.  Prostate 
specimens were placed in molds for sectioning to ensure orientation between histology and imaging 
slices [18, 19] (Figure 2-a).  All prostate sections were analysed by an experienced uro-pathologist 
(more than 20 years of experience) without knowledge of SWE image findings.   Margin status 
including pathological stage of the disease was defined and compared to SWE imaging.  
 Statistical analyses 
All statistical analyses were performed using SPSS 22 (IBM Corporation, New York, US). Stiffness 
values of cancerous tissue and surrounding benign tissues were compared using paired Student t 
test. The α level was set at 0.05 to determine two-tailed significance. Receiver operator 
characteristic curves (ROC) were plotted for stiffness values followed by application of maximum 
Youden index (sensitivity-[1-specificity]), indicating sensitivity and specificity are equally important 
to determine optimal cut-off values between tissues that was cancerous or benign[20]. For the 
purpose of cross-validation and control, ten-fold cross validation was implemented. We randomly 
split data into 10 subgroups with identical size, each subgroup was selected and served as a 
testing database while the remaining 9 subgroups were used for training. The performance was 
repeated for 9 additional times with different subgroups served as testing database. Correlations 
between cancer stiffness and Gleason Scores (GSs) were calculated.  Elasticity values representing 
each GS were graphed using box-and-whisker plots. Finally, tissue stiffness was correlated with 
histopathology outcomes to define significant PCa. 
Results 
Mean age of the cohort was 67.6±5.4 years with a mean PSA of 11.8±8.1 ng/ml (range 0.9 to 47).  
Mean prostate volume was 66.9±30.4 ml (range 20 to 207).  Seven participants only had GS 6 
diseases (3+3: 3%); more than half of the participants had Gleason score (GS) 7 diseases (3+4: 48% 
and 4+3: 17%); notably, almost one-third of participants in this series demonstrated high GS disease 
(3+5: 10%, 4+4: 1%, 4+5: 21%) (Table 1). There were two level of analyses carried out.  
For participant-level analyses, only averaged index lesion scores were considered when assessing 
performance of SWE for low grade PCa (GS=6), intermediate PCa (GS=7) or high-grade PCa (GS≥8).  
This is seen in Table 2.  Stiffness data using Young’s modulus (kPa) matched with histopathology 
demonstrates Young’s Moduli were significantly higher for high grade PCa compared with low grade 
disease. In the entire cohort, the median values of Young’s moduli for benign, low, intermediate and 
high grades were 58.3kPa, 91.6kPa, 102.3kPa and 131.8kPa, respectively (Figure 4).  A maximum 
Youden index of 64.6% (sensitivity: 96.8%, specificity: 67.8%) was found with a cut-off value of 
82.6kPa for SWE in being able to detect malignant versus benign tissue (p<0.05) after ten-fold 
cross validation (Table 3). When 82.6kPa was applied to all index lesions, AUC was 0.976 (p<0.05) 
(Figure 3). 
In tumour-level analyses, 509 cancer foci from total of 2544 regions (12 regions from 212 patients 
[Figure 2-b]) were marked from the whole-mount pathology.  The cancer distribution map was 
shown in Table 4-a. 10.8% (55/509), 25% (127/509) and 64.2% (327/509) of cancer foci were <5mm, 
5-10mm and > 10mm in size respectively. GS 3+4 was the most common cancer accounting for 
58.2% (296/509) of all the cancer foci. Table 4-b illustrated that SWE identified cancer on the 
distribution map using 82.6 kPa as a cut-off value. Stiffness of the identified cancers are displayed in 
Table 4-c.  As such, after considering the size of all cancers, there were no significant differences for 
tissue stiffness across differing sizes of cancer foci. However, the mean value of Young’s modulus of 
GS 6 to 9 increased from 91.9kPa (GS 3+3) to 126.7kPa (GS 4+5), respectively. The mean value for all 
lesions was 106.3kPa. Table 4-d showed that sensitivity for SWE to detect <5mm cancers was 
much lower than 5-10mm and > 10mm Cancers (30.9% vs 68.5% and 92.4%), only 9 of 32 GS6 and 
<5mm cancers were found by SWE. 
Figure 5 presented diagnostic results of clinically significant cancer, while demonstrating SWE 
outcomes for sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) compared with histopathology results. Sensitivity, specificity, PPV and NPV of SWE for 
clinically significant cancer were 88.6% (95% CI 85.1%-91.6%), 97.3% (CI 96.6-98.0%), 86.3% (CI 83.0-
89.1%) and 97.8% (CI 97.2-98.3%), respectively (p<0.05).  
Figure 6 is a representative figure demonstrating a 70 years old patient’s ultrasound and pathology 
images. MRI was negative, biopsy showed GS 3+3, SWE was as high as 300kPa and suggested 
prostate capsular breach in peripheral area.  These were all summarised in Figure 6. Prostate stones 
were seen in B-mode ultrasound, LRP pathology images confirmed cancer with extraprostatic 
extension (EPE) and GS 4+5. For the entire cohort, when pathologic stages were more aggressive, we 
were able to detect margins status/capsular breaches with a sensitivity and specificity of 73.9% 
(68/92) and 80.8% (97/120), respectively (Table 5, p<0.05).  All patients with capsular breach had 
either high grade disease (>GS 7) or large sized lesions (>10mm).  When cancerous tissue size was 
more than 10mm and within 2mm of edge of prostate, there was 90% risk of positive surgical 
margin as assessed by prostate whole-mount histopathology.   
Discussion 
Observations of the present study illustrated that TRUS SWE demonstrated strong diagnostic 
performance in clinically localised PCa.  We showed that transrectal SWE could identify PCa coupled 
with an ability to distinguish between clinically significant and low-risk PCa.  We also demonstrated 
that tissue stiffness measurements (Young's modulus) estimated from 12 different regions of the 
prostate gland using a cut-off value (82.6kPa) identified significant differences between benign and 
malignant tissue. The cut-off value was based on internal validation using ten-fold cross validation 
method.  Particularly, we found that significant lesions (GS≥7) demonstrate higher Young’s moduli 
compared with benign and non-significant lesions (GS≤6).  Lastly, TRUS SWE also showed strong 
performance to predict cancer stage and status of surgical margins.  These data represented a 
significant contribution to the body of knowledge associated with utilising transrectal B-Mode 
ultrasonography for screening PCa.     
Despite various innovative imaging technologies aimed at improving detection and characterisation 
of PCa, calculating individual risk for presence of clinically significant PCa remains poor.  Histology 
using prostate biopsies remains the gold standard for PCa diagnosis.  However, TRUS guided biopsy 
is an invasive procedure with known risks including acute bleeding, sepsis, urinary retention and 
even death [21-23]. Therefore, image fusion techniques, Doppler and contrast enhanced ultrasound 
methods have been used to improve detection of PCa while also aiming to reduce  the number of 
biopsies performed and minimising  the occurrence of adverse events  [24-27].  
A number of reports, including recent guidelines have reported on the improved diagnostic 
performance of SWE with respect to PCa [11, 15]. However, previous studies have lacked power and 
used mostly grey scale based ultrasound guided biopsies as reference standard.  Accordingly, there 
are many original features of the present study.  Firstly, the present study is the largest cohort that 
has been used to analyse the utility of SWE in comparison to final histopathology reports from 
specimens using whole-mount radical prostatectomy specimens.    Secondly, we confirmed that 
orientation involving what is observed on imaging is consistent with final histopathology slides via 
implementation of rapid prototyping and mold based technology [18].  
In our study, we also observed that SWE showed strong diagnostic performance regarding different 
prostatic tissues of various regions. Cancer foci could be detected or visually colour-coded by real-
time SWE scan. We demonstrated using this technique that benign tissue had an appreciably lower 
stiffness compared with cancer foci. Using this advanced SWE ultrasound imaging technique, we 
also identified an accurate cut-off value for distinguishing suspicious cancer areas from benign 
prostatic tissue. Ten-fold cross validation was performed and the averaged cut-off value was 
82.6kPa (Table 3). Accordingly, these observations have immediate implications for therapy and 
follow-up care for patients.  For example, 1) low grade PCa might not need active treatment and 2) 
if PCa can be reliably identified, follow-up care can be closely tracked to help in reducing 
mistreatment rate with high diagnostic performance and the ability of SWE to differentiate between 
different grades of cancer, this technology could be tested for reliable monitoring in an active 
surveillance cohort.   A higher cut-off compared to previous studies is due to a higher proportion of 
men with high grade disease.  Present series also represented unscreened men for prostate cancer.     
It may be skewed due to the fact that most men with significant disease will opt for radical surgery 
as treatment option.  Our cut-off value was based on robust cross-validation technique and using a 
better reference standard of radical prostatectomy histology.   
Positive surgical margins and extraprostatic extension of cancer may cause increased biochemical 
recurrence(BCR)[28]. These types of patients require extended PSA follow-up time and may also 
necessitate salvage treatments after failed LRP. Therefore, preoperative testing with SWE has shown 
the ability to predict positive surgical margins following, while also demonstrating the potentiality to 
assist surgical plans and predict future adjuvant treatment.  
There are several limitations of the present study.  We estimated diagnostic performance of SWE in 
men with histopathologically confirmed PCa (selection bias).  Whether similar results would also be 
observed in men with suspected PCa or in other screening setting needs further study.  A potential 
learning curve associated with applying the SWE technique was not assessed and procedures were 
carried out by single surgeon at a single center site.   Nevertheless, the robust protocol of the 
present study coupled with encouraging findings provide support that further research is needed in 
this area.  
Conclusions 
The TRUS SWE imaging demonstrated a high reliability and accurately distinguished PCa from benign 
tissues while identifying a cut-off stiffness value. Moreover, SWE technology provided a high 
reliability in distinguishing PCa based on their phenotypes (grades of PCa). At last, the technology 
has also shown good diagnostic performance in the detection of margin status and stage of the 
disease.  
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Figures captions 
Figure 1 a: Images shows shear waves generation and plane of travel creation in two planes; b: 
ultrasound transducer measuring travel of shear waves and conversion of this into (c) colour-coded 
elastogram with red indicating high stiffness and blue representing less stiff tissue. 
 
 
 
Figure 2 Comparison of histopathology results with 12- region SWE images obtained in a 73 years old 
patient. a: whole set of prostate slices in three locations (base, mid and apex of gland); b: 12-regions 
prostate imaging template; c: representative ultrasound images in apex part (Note SWE image, top; 
B-mode image, bottom) 
 
 
 
 
Figure 3 ROC Curve for cancer detection of prostate cancer shows an AUC of 0.97 
 
 
 
 
 
 
 
 
 
Figure 4 Box-and-whisker plot shows the tissue stiffness values of benign and different grade of 
malignant lesion of prostate according to the Gleason Grade  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Diagnostic accuracy for detection of clinically significant prostate cancer (GS>6, size >5mm) 
on SWE imaging in comparison to reference standard test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:  Illustrates an example of a 70 years old patient, MRI negative, biopsy GS 3+3, SWE shows a 
high tissue stiffness as 300kPa and prostate capsular breach in peripheral area (a), prostate stones 
show in B-mode ultrasound as hypo-intensive signal and confirm in prostate specimen slice (b), 
Whole-mount prostate pathology confirmed high grade cancer (GS4+5) with extraprostatic 
extension (EPE) pT3 disease (c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tables captions: 
Table 1 Baseline patient characteristics 
Table 2 SWE-measured stiffness map of benign and cancerous lesions with various grades 
Table 3: averaged AUC, cut-off value, sensitivity and specificity for SWE cancer detection from 10-
fold cross validation 
Table 4:  Distribution map: (a) Total number of cancer foci seen on histopathology distributed by 
size and Gleason score; (b) SWE identified lesions out of total seen on histopathology; (c) stiffness 
of SWE identified lesions and (d) SWE sensitivity for different sizes and grades of cancers.  
Table 5 Margin status of whole mount prostate specimens: performance of SWE (index test) in 
comparison to histopathology (reference test) 
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Table 1. Characteristics of the cohort 
 
Table 2: SWE-measured stiffness map of benign and cancerous lesions with various grades 
 
 
 
Table 3: averaged AUC, cut-off value, sensitivity and specificity for SWE cancer detection from 10-
fold cross validation 
 
 
 
 
 
 
 
 
 
Table 4:  Distribution map cancer foci seen on histopathology. (a) Total number of lesions distributed by size and Gleason score  (b) SWE identified lesions 
out of total seen on histopathology (c) stiffness of SWE identified lesions and (d) SWE sensitivity for different sizes and grades of cancers.  
 
 
 
 Table 5 Margin status of whole mount prostate specimens: performance of SWE (index test) in 
comparison to histopathology (reference test) 
 
